Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | TAS1R3 | Q7RTX0 | 9/20 | 0.52 |
| ▸ | TAS1R1 | Q7RTX1 | 8/20 | 0.52 |
| ▸ | TAS1R2 | Q8TE23 | 7/20 | 0.52 |
| ▸ | TOP1 | P11387 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | TERT | O14746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL139991 | 1.00 | HDAC6 (0.55) | HDAC6TAS1R3TAS1R1TAS1R2TOP1 | |
| SCHEMBL108094 | 1.00 | HDAC6 (0.55) | HDAC6TAS1R3TAS1R1TAS1R2TOP1 | |
| SCHEMBL14194895 | 0.82 | ALDH1A1 (0.58) | TAS1R3TAS1R1TAS1R2TOP1KDM4E | |
| SCHEMBL15069968 | 0.82 | ALDH1A1 (0.58) | TAS1R3TAS1R1TAS1R2TOP1KDM4E | |
| SCHEMBL15069950 | 0.82 | ALDH1A1 (0.58) | TAS1R3TAS1R1TAS1R2TOP1KDM4E | |
| SCHEMBL15069964 | 0.82 | ALDH1A1 (0.58) | TAS1R3TAS1R1TAS1R2TOP1KDM4E | |
| SCHEMBL1355687 | 0.79 | HTT (0.58) | HDAC6TAS1R3TAS1R1GAAMAPT | |
| SCHEMBL14608938 | 0.76 | HDAC6 (0.44) | HDAC6TAS1R3TAS1R1TAS1R2TOP1 | |
| SCHEMBL10016125 | 0.76 | TAS1R3 (0.54) | TAS1R3TAS1R1TAS1R2TOP1KDM4E | |
| SCHEMBL13240250 | 0.76 | TAS1R3 (0.54) | TAS1R3TAS1R1TAS1R2TOP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163957-B2 | Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes and parkinson's disease | PROTEOTECH, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163957-B2 | Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes and parkinson's disease | PROTEOTECH, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110172239-A1 | Compounds, Compositions and Methods for the Treatment of Amyloid Diseases and Synucleinopathies such as Alzheimer's Disease, Type 2 Diabetes and Parkinson's Disease | PROTAMED, INC. | 2011-07-14 | — | — | US | disclosed |
| US-20110172239-A1 | Compounds, Compositions and Methods for the Treatment of Amyloid Diseases and Synucleinopathies such as Alzheimer's Disease, Type 2 Diabetes and Parkinson's Disease | PROTAMED, INC. | 2011-07-14 | — | — | US | disclosed |
| US-20070276034-A1 | Compounds, compositions and methods for the treatment of synucleinopathies | PROTEOTECH, INC. | 2007-11-29 | — | — | US | disclosed |
| US-20070276034-A1 | Compounds, compositions and methods for the treatment of synucleinopathies | PROTEOTECH, INC. | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276034-A1 | Compounds, compositions and methods for the treatment of synucleinopathies | SNCA, PARK7, COMT | HDAC6 246/4885TAS1R3 4364/4885TAS1R1 4662/4885 |
| US-20110172239-A1 | Compounds, Compositions and Methods for the Treatment of Amyloid Diseases and Synucleinopathies such as Alzheimer's Disease, Type 2 Diabetes and Parkinson's Disease | IAPP, SNCA, APP | HDAC6 3468/4885TAS1R3 4450/4885TAS1R1 4676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.